Nasdaq · Healthcare
COLLEGIUM PHARMACEUTICAL, INC (COLL)
As-reported financials and recent SEC filings for COLLEGIUM PHARMACEUTICAL, INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$780.6M
Net income
$62.9M
Net margin
8.1%
Diluted EPS
$1.73
ROE
20.8%
P/E (TTM)
17.8×
Market cap
$1.19B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $780.6M | $631.4M | $566.8M | $463.9M | $276.9M |
| Gross profit | $463.3M | $377.3M | $326.2M | $209.5M | $150.6M |
| Operating income | $179.6M | $169.9M | $167.0M | $33.3M | $17.6M |
| Net income | $62.9M | $69.2M | $48.2M | $-25.0M | $71.5M |
| Diluted EPS | $1.73 | $1.86 | $1.29 | $-0.74 | $1.86 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-10
View on EDGAR →S-82026-06-01
View on EDGAR →S-82026-06-01
View on EDGAR →42026-05-20
View on EDGAR →42026-05-18
View on EDGAR →32026-05-18
View on EDGAR →1442026-05-18
View on EDGAR →42026-05-18
View on EDGAR →Go deeper on COLL
Search COLLEGIUM PHARMACEUTICAL, INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.